Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign

Commun Dis Public Health. 2002 Sep;5(3):220-5.


The UK was the first country to introduce meningococcal serogroup C conjugate vaccination. The vaccine was incorporated into the routine infant immunisation schedule and was offered to all under 18 year olds in a catch-up campaign. The vaccine has been well accepted in infants receiving routine vaccination, with coverage around 89%. Coverage in older children targeted in the catch-up campaign was above 85% up to the age of 14, and was lowest (43%) in 15-17 year olds not in education. The winter of 2000-01 was the first meningococcal season following the offer of the vaccination to all children and adolescents. The incidence of serogroup C disease in the targeted age groups fell by 80%, and the number of deaths in laboratory confirmed cases in 0-19 year olds decreased from 78 to 8 between 1998-99 and 2000-01. The incidence of serogroup B disease in all age groups was slightly higher in 2000-01 than previous years, and there was an increase in the incidence of serogroup C disease in those aged over 20 during the study period, leading to the extension of the vaccination campaign to 20-24 year olds.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • England / epidemiology
  • Female
  • Humans
  • Incidence
  • Infant
  • Male
  • Mass Vaccination*
  • Meningococcal Infections / epidemiology*
  • Meningococcal Infections / mortality
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / therapeutic use*
  • Middle Aged
  • Neisseria meningitidis, Serogroup C* / isolation & purification
  • Outcome Assessment, Health Care
  • Treatment Outcome
  • Wales / epidemiology


  • Meningococcal Vaccines
  • serogroup C meningococcal conjugate vaccine